RARE vs SEM · rev $560.2M vs P/E 15, rev $1.31B
Ultragenyx (RARE) versus Select Medical Holdings (SEM) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
Select Medical Holdings (SEM) is a medical care facilities company listed on NYSE.
Latest reported RARE revenue for 2024-12-31 was $560.2M. Net income was -$569.2M. Revenue was up 29.0% from 2023-12-31 to 2024-12-31. RARE currently screens at market cap $2.79B.
Latest reported SEM revenue for 2024-12-31 was $1.31B. Net income was $3.8M. Revenue was up 3.2% from 2024-09-30 to 2024-12-31. SEM currently screens at market cap $2.05B and trailing P/E 15.5.
RARE currently screens at market cap $2.79B. SEM currently screens at market cap $2.05B and trailing P/E 15.5.
Not investment advice. Open the RARE and SEM stock pages for the full models.
Not investment advice.